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Background : Garcinia mangostana L. has been extensively used for years as antioxidant and anti-inflammation. 
However, its role in the context of endothelial disease was lacking.
Objectives : To assess the effect of add-on G. mangostana L. extracts on endothelial dysfunction in type 2 diabetes 
subjects with high-risk Framingham score, compared to placebo.
Methods : This was a prospective cohort study conducted in type 2 diabetes subjects with high-risk Framingham 
score. Subjects were randomized into two groups. The first group received 2,520 mg/day of G. mangostana L. 
extract. The second group was given a placebo for 90 days. The outcome measure of our study was the levels of 
endothelial progenitor cell (EPC), circulating endothelial cell (CEC), nitric oxide (NO), tumor necrosis factor-α 
(TNF-α), interleukin-1 (IL-1), IL-6, hemoglobin A1c (HbA1c), high-sensitivity C-reactive protein (hs-CRP), 
malondialdehyde (MDA), Superoxide dismutase (SOD) and fasting blood glucose. Multiple linear regression was 
used to determine the correlation and effect estimate.
Results: A total of 49 patients were included in our study. Of those, elevated levels of EPC and SOD were observed 
in treatment group compared to placebo. On the other hand, the level of CEC, IL-1, Il-6, NO, MDA, TNF-α, fasting 
blood glucose and HbA1c was found significantly lower than placebo.
Conclusion: Garcinia mangostana L. extract is associated with an increased levels of EPC and SOD, and it is also 
correlated with a decreased levels of CEC, IL-1, Il-6, NO, MDA, TNF-α, fasting blood glucose and HbA1c.
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Anti-inflammation
 Endothelial dysfunction has been widely known to contrib-
ute in the development of atherosclerosis and its complication. Briefly, 
the endothelium place an important role as a mechanical and biological 
barrier between the blood and the vascular wall. This process requires 
a balance between pro and anti inflamatory mediators. In the theory of 
atherosclerosis, it was known that NO, IL1, and IL6 were involved in 
the development of endothelial dysfunction. Moreover, recent studies 
proposed that the development of endothelial dysfunction was also 
triggered by EPC and CEC.1,2 EPCs are immature cells that are capable 
of differentiating into mature endothelial cells. While CECs are mature 
cells that separated from the intimal layer as a response to endothelial 
injury.2,4 Therefore, a new potential therapy having a target site at 
those components might provide a promising outcome. 
 Garcinia mangostana L. is one of the medical plants found in 
Asia, particularly in South East Asia. The role of  Garcinia mangostana 
L. as anti-inflammatory agent has been widely reported. Subsequently, 
it was also reported that Garcinia mangostana L. plays a beneficial role 
in type 2 diabetes patients with stable coronary artery disease.5,6 
However, the evidence of G. mangostana effect on type 2 diabetes 
mellitus subjects with high-risk Framingham scores was limited.
 Our present study, therefore, aimed to assess the effect of  
Garcinia mangostana L. extract on the levels of  EPC, CEC, NO, TNF-α, 
IL-1, IL-6, HbA1c, hs-CRP, MDA, SOD and fasting blood glucose. Our 
current findings were expected to provide the primary data of the role 
of Garcinia mangostana L. extract in the development of endothelial 
dysfunction. 
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2. Methods
2.1. Research Design
 A prospective cohort study was conducted in dr. Saiful 
Anwar Hospital, Malang, Indonesia, during the period November 2018 
and January 2019. To guide the protocols in our study, we used 
Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) checklist.7
2.2. Ethical approval
 This study has been approved by the Institutional Review 
Board, Faculty of Medicine, Universitas Brawijaya, Malang, Indonesia 
(No: 64/EC/KEPK/03/2018). All participants included in our present 
study were explained about the aim, purpose, benefit, and the risk of 
this study. All participants had given the written informed consent prior 
to be involved in our study. All participants in our study were 
voluntary, and no incentive was given. 
2.3. Participants & eligibility criteria
 Participants were recruited using a random sampling 
procedure. The inclusion criteria were (1) Adult patients age 50 to 80 
years with Framingham score >20 (high-risk) based on clinical, 
biochemical, anthropometry, and electrocardiographic criteria; (2) 
clinically stable and recovered; (3) on standard medication of moder-
ate-high intensity statin, anti-diabetes therapy such as metformin, 
sulfonylurea, acarbose or insulin, ACE inhibitor or angiotensin receptor 
blocker (ARB) or calcium channel blocker, and/or beta-blocker. 
Patients with the following criteria: (1) heart failure NYHA class III-IV 
patients; (2) elevated levels of AST and ALT three times normal upper 
limit; (3)  eGFR <30 ml/min/1.73 m2 (by MDRD glomerular filtration 
rate equation)8; (4) creatinine level >1.5 mg/dl; (5) the value of APTT 
and INR twice of normal limit; (6) ongoing infection or inflammatory 
conditions (leukocytes >10,500; laboratory cut-off); (7) history of 
neoplasms or other malignancy were excluded from the study. 
2.4. Outcome measure
 We collected demographic data including gender, age, body 
weight and height, body mass index (BMI), blood pressure, heart rate, 
lipid profile (i.e., triglycerides, total cholesterol, LDL and HDL choles-
terols), fasting plasma glucose and HbA1c. The high-risk Framingham 
score was retrieved from the demographic data and clinical history.9 
 
 The outcome measure of our study was the levels of EPC, 
CEC, NO, TNF-α, IL-1, IL-6, HbA1c, hs-CRP, MDA, SOD, and fasting 
blood glucose after 90 days of treatment. 
2.5. Statistical Analysis
 Statistical analysis was performed using the Statistical 
Package for Social Sciences software (SPSS) for Windows, version 16, 
Chicago, USA. Data were presented as mean ± standard deviation 
(SD). The correlation and effect estimate in our present study were 
determined using multiple linear regression. The p-value of less than 
0.05 was considered having significant association.
3. Results
3.1. Patients selection
 A total of 90 patients were identified during study period. Of 
those, 13 patients were excluded because of low-intensity statin used 
(n=11), creatinine level >1.5 mg/dl (n=1), and estimated GFR <30 
ml/min/1.73 m2 (n=1). Additionally, a total of 28 patients were 
excluded because of having low risk of Framingham score. Totally, we   
included 49 patients in our study. Of them, a total of 23 patients receive
G. mangostana L. extract. While a total of 26 patients received placebo. 
A flowchart describing the eligibility process in our present study is 
provided in Figure 1.
Figure 1. A flowchart of patients selection in this study
3.2. Baseline characteristics
 The majority of patients were female (77.55%, n=38), with 
the mean age was 64.16 years, and the mean BMI was 25.92 kg/m2. 
Other baseline characteristics were provided in Table 1. Our statistical 
analysis confirmed that the baseline characteristics between treatment 
and control groups were not significantly different (p>0.05), suggest-
ing that the data between the treatment and control groups were 
distributed homogenously.
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Table 1. Baseline characteristics of patients included in our study
Note; BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; bpm, beats per minute.
3.3. Main findings
 The levels of lipid profile between treatment and control 
group were not significantly different. Moreover, the level of fasting 
blood glucose was not significantly different between treatment and 
control groups. However, a decreased level of HbA1c was observed in 
treatment group compared to control group (Table 2, Figure 2).
 Concerning antioxidant effect, the level of MDA was 
observed lower in treatment group compared to control group. Subse-
quently, the levels of CEC, IL-1, Il-6, NO, MDA, and TNF-α were found 
significantly lower in treatment group compared to control group 
(Table 3, Figure 3 and 4). Furthermore, the levels of EPC and SOD were 
significantly higher in treatment group compared to control group 
(Table 3, Figure 5).
Figure 2. Add-on G. mangostana L. extract could improve glycemic 
profile in comparison to placebo
Table 3. The effect of G. mangostana L. extract as antioxidant, anti-in-
flammation, and improvement of endothelial dysfunction after 90 days 
of treatment
Note; IL-1, interleukin-1; TNF-α, tumor necrosis factor-α; EPC, endothelial 
progenitor cell; CEC, circulating endothelial cell
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Characteristics All n=49 
 
Add-on 
Placebo 
n=26 
(53,1%) 
  
Add-on G. 
mangostana L. 
extract 
n=23 (46.9%) 
p-value 
Sex 
Male (no. of patients) 
Female (no. of patients) 
 
11 
38 
 
6 
20 
 
5 
18 
0.911 
Age (yr, mean) 64.16 64.08 64.08 0.910 
Weight (kg) 61.12 63.31 58.65 0.152 
Height (cm) 153.73 153.31 154.22 0.680 
BMI (kg/m2) 25.92 26.95 24.75 0.117 
Systolic BP (mmHg) 149.22 146.62 152.17 0.406 
Diastolic BP (mmHg) 87.53 88.35 86.61 0.648 
Heart rate (bpm) 76.22 73.23 79.61 0.069 
Triglycerides (mg/dl) 154.12 160.38 147.04 0.608 
Total cholesterol (mg/dl) 189.94 189.12 190.87 0.882 
HDL cholesterol (mg/dl) 47.38 46.79 48.04 0.716 
LDL cholesterol (mg/dl) 107.07 108.77 105.15 0.685 
Fasting blood glucose 
(mg/dl) 
154.55 163.31 144.65 0.290 
HbA1c (%) 8.12 8.45 7.75 0.017 
 
 
G. mangostana 
extract (n=26) 
  
Placebo 
(n=23) P-value 
 
Anti-inflammation 
 IL-1 -12.4816±20.3 11.9±32.8 0.003 
 IL-6 -64.330±121.5 48.6135±121.5 0.002 
 TNF-  -178.8±108.8 -56.6±86.6 0.000 
hs-CRP -116.4±107.6 -49.6±78.5 0.000 
Anti-oxidant 
 Malondialdehyde (MDA)  -6.9±9.2 3.09±6.3 0.000 
 Superoxide dismutase (SOD) 0.099±0.76 -0.40±0.71 0.023 
Parameters of endothelial dysfunction 
 Nitric oxide (NO) -6.87±12.6 -1.01±3.22 0.027 
 EPC 17.27±23.20 -20.55±29.6 0.000 
 CEC -65.3±78.07 -6.1374±39.49 0.002 
Lipid profile 
Glycemic profile  
 
 Add-on G. mangostana L. extract (n=23)  
  
Add-on Placebo 
(n=26) P-value 
Total cholesterol -1.0435 3.3846 0.650 
HDL 2.2174 -1.0231 0.140 
LDL -9.0652 0.6500 0.116 
Triglycerides -7.6522 -10.0000 0.901 
HbA1c -0.81±1.01 0.06±0.80 0.002 
Fasting blood glucose  -26.4±4.7 -15.11±43.9 0.336 
Table 2. The effect of adding G. mangostana L. extract on lipid and glycemic profiles after 90 days of treatment
Note; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HbA1c, hemoglobin A1c
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       (A)       (B)
Figure 3. Increase of SOD level (A) and decrease of MDA (B) after 
adding G. mangostana L. extract on top of treatment, compared to 
placebo
      (A)       (B)
       (C)
Figure 4. The effect of add-on G. mangostana L. extract to reduce the 
level of TNF-a (A), hs-CRP (B), IL-1 and IL-6 (C) in comparison to 
placebo
Figure 5. The effect of add-on G. mangostana extract L. in improving 
endothelial dysfunction after 90 days, compared to placebo
4. Discussion
 Out current findings confirmed that the administration of G. 
mangostana L. extract was associated with elevated level of EPC and,   
SOD and decreased level of CEC, NO, and MDA. Our findings suggested 
that G. mangostana L. extract might play an important role as an antiox-
idant in the development of endothelial dysfunction. Briefly, in the 
process of oxidative stress, reactive oxygen species (ROS) accumulates 
through the protein subunit p66. Antioxidant protection occurs through 
catalase, SOD, and glutathione peroxide (GPx), which eliminate the 
excessive ROS. The alteration to protein p66 and SOD function causes 
endothelial dysfunction.10,11 Atherosclerosis leads to narrowing of blood 
vessels and is more common in diabetes mellitus. Hyperglycemia and 
hypercholesterolemia in type 2 DM predispose to the development of 
atherosclerotic plaque, which can be stable or unstable. Mechanisms 
such as increased inflammation, oxidative stress, foam cell deposition, 
endothelial dysfunction, and angiogenesis will facilitate plaque rupture. 
12 Furthermore, hyperglycemia has a detrimental effect as in the forma-
tion of advanced glycated end products (AGE) and increases the 
production of reactive oxygen species (ROS) through NADPH oxidase 
activation; both are the main causes of endothelial progenitor cells 
(EPCs) apoptosis. AGE itself, in turn, further increases ROS production, 
and also promotes NF-κB transcription. NF-κB is crucially involved in 
inflammation via IL-1 and TNF-α.13 Xanthone and other bioactive have 
a role as antioxidants in preventing AGE formation and reducing ROS. 
Therefore, the extract of G. mangostana L. can be used as a supplemen-
tal antioxidant therapy.10,11 
 The evidence concerning the role of G. mangostana L. extract 
in the process of atherosclerosis was limited. However, several studies 
have reported. Abdallah et al.14 suggested that G. mangostana L. extract 
could able to inhibit the formation of AGE in the cytoplasm. This 
anti-AGE property resulted from an inhibition of free radicals and 
glycation reaction to monosaccharide. Therefore, it prevented the 
development of diabetic complications, whereas Ibrahim et al.15 showed 
that the anti-diabetic property of G. mangostana L. extract was found in 
its bioactive xanthone. However, many clinical trials, both in vivo or in 
vitro, are required to evaluate further.16
 Moreover, we also found that the levels of IL-1, IL-6, TNF-α, 
and hs-CRP were significantly lower in treatment group compared to 
placebo. Our result suggested that the administration of G. mangostana 
L. extract was associated with anti-inflammation effect. Briefly, both 
inflammatory and oxidative stress lead to endothelial dysfunction, and 
they were worsened by hyperglycemia in type 2 DM. Besides, the 
accumulation of ROS and NO bioavailability are imbalanced. Alexandru 
et al.10 showed that EPC dysfunction in type 2 DM was related to 
oxidative stress and ROS formation. SOD activity as an antioxidant 
enzyme was also found reduced. Mobilization of EPC from bone 
marrow and homing to the site of injury requires enough NO. 
Therefore, EPC level decreases in endothelial dysfunction. Unlike EPC, 
the level of CEC increases during injury as CECs detach from the injured 
endothelial layer.4,13,11, 17-20 On the other hand, a study by Jindarat.17 
suggested that xanthone could increase the activation of MAPK, c-Jun 
and EIK-1, and NF-κB pathways activation. Enhancing the activation of 
the NF-κB pathway associates with the increase of cytokines produc-
tion, including IL-1, IL-6, and TNF-α. Those inflammatory markers 
reduced when the pathways were inhibited.17
 In our current study, several important limitations were 
found. First, several factors that might govern anti-inflammation and 
anti-oxidation effects in endothelial diseases such as psychological 
stress, drug adherence, and lifestyle status were not observed. Second, 
the result of our current study should be interpreted with caution due 
to the relatively small sample size. Third, the design of our present 
study was prospective cohort. Further studies using randomized control 
trial might be required to obtain a higher level of evidence. Forth, the 
sample frame of our present study was limited to a single center. 
Further studies with multicenter sampling method might be required. 
5. Conclusion
 Administration of Garcinia mangostana L. extract is associat-
ed with the improvements of endothelial dysfunction by regulating 
increased levels of in EPC and SOD and decreased levels of CEC, IL-1, 
Il-6, NO, MDA, TNF-α, fasting blood glucose and HbA1c. Our findings 
may provide that Garcinia mangostana L. extract has the potential as 
promising adjuvant therapy in coronary artery disease treatment and 
the development of diabetic vascular complications.
24
O. Handayani, et al. Heart Sci J 2020; 1(1): 21-25
6. Declarations
6.1. Ethics Approval and Consent to participate 
This study was approved by local Institutional Review Board, and all 
participants have provided written informed consent prior to involve in 
the study.
6.2. Consent for publication
Not applicable.
6.3. Availability of data and materials
Data used in our study were presented in the main text.
6.4. Competing interests
Not applicable.
6.5. Funding source
Not applicable.
6.6. Authors contributions 
Idea/concept: OH. Design: OH. Control/supervision: DS. Data 
collection/processing: OH. Extraction/Analysis/interpretation: OH, DS, 
MSR. Literature review: DS, MSR. Writing the article: OH. Critical 
review: DS, MSR, BS, CTT, DH. All authors have critically reviewed and 
approved the final draft and are responsible for the content and similar-
ity index of the manuscript.
6.7. Acknowledgements
We thank to Brawijaya Cardiovascular Research Center.
References
25
Vandenbroucke JP, Von Elm E, Altman DG, et al. Strengthening the 
Reporting of Observational Studies in Epidemiology (STROBE): 
explanation and elaboration. Ann Intern Med 2007;147(8):W-163. 
Levey AS, Coresh J, Bolton K, et al. K/DOQI clinical practice 
guidelines for chronic kidney disease: Evaluation, classification, and 
stratification. Am. J. Kidney Dis. 2002;39(2 SUPPL. 1). 
Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, 
Kannel WB. Prediction of coronary heart disease using risk factor 
categories. Circulation [Internet] 1998 [cited 2020 Apr 
2];97(18):1837–47. Available from: https://www.ahajour-
nals.org/doi/10.1161/01.CIR.97.18.1837
Wihastuti TA, Sargowo D, Tjokroprawiro A, Permatasari N, Widodo 
MA, Soeharto S. Vasa vasorum anti-angiogenesis through H2O2, 
HIF-1α, NF-κB, and iNOS inhibition by mangosteen pericarp 
ethanolic extract (Garcinia mangostana Linn) in hypercholester-
ol-diet-given Rattus norvegicus Wistar strain. Vasc Health Risk 
Manag 2014;10:523–31. 
Wihastuti TA, Sargowo D. The Comparation of Activation Nuclear 
Factor Kappa Beta (NFkB) at Rattus Novergicus Strain Wistar 
Induced by Various Duration High Fat Diet. World Acad Sci Eng 
Technol [Internet] 2012 [cited 2020 Apr 2];6(9):216–8. Available 
from: https://publications.waset.org/8466/the-comparation-of-ac-
t i v a -
tion-nuclear-factor-kappa-beta-nfkb-at-rattus-novergicus-strain-wis
tar-induced-by-various-duration-high-fat-diet-hfd
Wihastuti TA, Widodo MA, Heriansyah T, Sari NAK. Study of the 
inhibition effect of ethanolic extract of mangosteen pericarp on 
atherogenesis in hypercholesterolemic rat. Asian Pacific J Trop Dis 
2015;5(10):830–4. 
Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A 
marker of atherosclerotic risk. Arterioscler. Thromb. Vasc. Biol. 
2003;23(2):168–75. 
Avogaro A, Albiero M, Menegazzo L, De Kreutzenberg S, Fadini GP. 
Endothelial dysfunction in diabetes: The role of reparatory mecha-
nisms. Diabetes Care. 2011;34(SUPPL. 2):S285. 
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Sen S, McDonald SP, Coates PTH, Bonder CS. Endothelial progeni-
tor cells: Novel biomarker and promising cell therapy for cardiovas-
cular disease [Internet]. Clin. Sci. 2011 [cited 2020 Apr 
2];120(7):263–83. Available from: https://portlandpress.com/clin-
s c i / a r t i c l e / 1 2 0 / 7 / 2 6 3 / 6 8 8 7 2 / E n -
dothelial-progenitor-cells-novel-biomarker-and
Alexandru N, Titorencu I, Frunzã S, Weiss E, Bãdilã E, Georgescu A. 
Endothelial Progenitor Cell Dysfunction in the Pathogenesis of 
Vascular Complications of Diabetes. In: Mechanisms of Vascular 
Defects in Diabetes Mellitus. Springer International Publishing; 
2017. p. 159–208.
Jung HA, Su BN, Keller WJ, Mehta RG, Kinghorn AD. Antioxidant 
xanthones from the pericarp of Garcinia mangostana (Mangosteen). 
J Agric Food Chem 2006;54(6):2077–82. 
Kartha CC, Ramachandran S, Pillai R. Mechanisms of Vascular 
Defects in Diabetes Mellitus. Springer; 2017. 
Yu C-G, Zhang N, Yuan S-S, et al. Endothelial Progenitor Cells in 
Diabetic Microvascular Complications: Friends or Foes? Stem Cells 
Int [Internet] 2016;2016:1803989. Available from: https://-
doi.org/10.1155/2016/1803989
Abdallah HM, El-Bassossy H, Mohamed GA, El-Halawany AM, 
Alshali KZ, Banjar ZM. Phenolics from Garcinia mangostana inhibit 
Advanced Glycation Endproducts formation: Effect on Amadori 
products, cross-linked structures and protein thiols. Molecules 
[Internet] 2016 [cited 2020 Apr 2];21(2):251. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26907243
Ibrahim SRM, Mohamed GA, Khayat MT, Ahmed S, Abo-Haded H, 
Alshali KZ. Mangostanaxanthone VIIII, a new xanthone from 
Garcinia mangostana pericarps, α-amylase inhibitory activity, and 
molecular docking studies. Brazilian J Pharmacogn [Internet] 2019 
[cited 2020 Apr 2];29(2):206–12. Available from: https://linking-
hub.elsevier.com/retrieve/pii/S0102695X18307075
Abdallah HM, El-Bassossy HM, Mohamed GA, El-Halawany AM, 
Alshali KZ, Banjar ZM. Mangostanaxanthones III and IV: advanced 
glycation end-product inhibitors from the pericarp of Garcinia 
mangostana. J Nat Med [Internet] 2017 [cited 2020 Apr 
2];71(1):216–26. Available from: http://www.ncbi.nlm.nih.gov/-
pubmed/27738860
Jindarat S. Xanthones from mangosteen (Garcinia mangostana): 
Multi-targeting pharmacological properties. J Med Assoc Thail 
[Internet] 2014 [cited 2020 Apr 2];97:S196–201. Available from: 
https://www.researchgate.net/publication/269771930_Xantho-
n e s _ -
from_mangosteen_Garcinia_mangostana_Multi-targeting_pharmac
ological_properties
McClung JA, Naseer N, Saleem M, et al. Circulating endothelial cells 
are elevated in patients with type 2 diabetes mellitus independently 
of HbA1c. Diabetologia [Internet] 2005 [cited 2020 Apr 
2];48(2):345–50. Available from: http://www.ncbi.nlm.nih.gov/-
pubmed/15660261
Aragona CO, Imbalzano E, Mamone F, et al. Endothelial progenitor 
cells for diagnosis and prognosis in cardiovascular disease. Stem 
Cells Int. 2016;2016. 
Fadini GP, Sartore S, Agostini C, Avogaro A. Significance of 
endothelial progenitor cells in subjects with diabetes [Internet]. 
Diabetes Care. 2007 [cited 2020 Apr 2];30(5):1305–13. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/17277037
